Assignee: Pfizer, Inc.

Location: Groton, CT
No. of patents: 21

Number	Title	Issue Date
7994120	Method of treating dyslipidemic disorder The invention provides methods of treating or preventing a condition or disorder associated with dyslipidemia with compositions comprising apolipoprotein-sphingomyelin complexes. The methods of the invention permit reduction, by 4- to 20-fold, of the amount of apoli...	08/09/2011
7432370	Chiral salt resolution The present application discloses compounds of the formula wherein R2 and R3 are as defined herein. The present application further discloses certain pyrrolol[2,3-d]pyrimidine ...	10/07/2008
7238676	Purine derivatives The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and composition...	07/03/2007
7232823	Cannabinoid receptor ligands and uses thereof Compounds of Formula (I) or (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein ...	06/19/2007
7232816	Substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medical products and processes for preparing them The invention relates to novel substituted pyrazolo[4,3-e]-diazepines of general formula: to pharmaceutical compositions containing them, to their use as medicinal products and to processes for preparing them.	06/19/2007
7166593	Glucocorticoid receptor modulators The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonist and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions conta...	01/23/2007
7112599	Oxazole compounds for the treatment of neurodegenerative disorders The present invention relates to compounds of the Formula wherein R3, R5, R6, R7, and Z, and other variables enumerated under one or more of R3, R5	09/26/2006
7107985	Pharmaceutical combination The present invention relates to a combination comprising (a) an adenosine A2a receptor agonist as define herein and (b) an adrenergic β2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of a...	09/19/2006
7030338	Pharmaceutical laser drilling system A laser drilling system forms an opening in the coating of a pharmaceutical dosage form and includes an orienting assembly to correctly orient dosage forms, a debris removal assembly to reduce buildup of and reduce exposure to drilling debris and a quality control a...	04/18/2006
6953791	Dipeptide derivatives This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which inc...	10/11/2005
6951850	Dipeptide derivatives This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which inc...	10/04/2005
6949577	Pharmaceuticals The present invention provides compounds of formula (I) as well as the use of such compounds in pharmaceutical compositions and methods of treatment. The compounds described herein represent a class of TAFIa in...	09/27/2005
6924280	Dipeptide derivatives This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which inc...	08/02/2005
6900230	Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents The present invention relates to compounds of the formula wherein R1, R3, R5, R6, and A are defined as in the specification, to pharmaceutical compositions containing them an...	05/31/2005
6864252	Hydrazinyl and nitrogen oxide pyrazoles The present invention relates to hydrazinyl and nitrogen oxide pyrazoles of the formula I: wherein the ring of the formula (R5)-A-(SOmR4), m, X, R1 through R5 are ...	03/08/2005
6852733	Sodium-hydrogen exchanger type 1 inhibitor NHE-1 inhibitor, methods of using the NHE-1 inhibitor and pharmaceutical compositions containing the NHE-1 inhibitor. The NHE-1 inhibitor is useful for the reduction of tissue damage resulting from tissue ischemia. ...	02/08/2005
6847840	System and method for statistical analysis of QT interval as a function of changes in RR interval A system and method for statistically analyzing QT interval as a function of changes in the RR interval. The system and method utilize three statistical comparisons to fully characterize the QT response: (1) the comparison of curves to give an overall effect; (2) th...	01/25/2005
6838458	5-(alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles The present invention relates to 5-(alkylidene-cycloalkyl)-pyrazoles and 5-(alkylidene-heterocyclyl)-pyrazoles of the formula I: wherein the ring of the formula (R5)-A-(SOmR4), m, B, ri...	01/04/2005
6828460	Resorcinol derivatives The present invention relates to the use of certain resorcinol derivatives as skin lightening agents. ...	12/07/2004
6677501	P2X7 receptor-deficient mice and uses thereof The invention provides non-human, genetically-modified mammals and genetically modified animals cells having a functionally disrupted P2×7 receptor gene. Also provided are methods for producing genetically modified mice in which one or both P	01/13/2004
4361649	Polycyclic ether antibiotic A new acidic polycyclic ether antibiotic has the formula: ##STR1## and can be prepared by the submerged aerobic propagation in aqueous nutrient media of Streptomyces halstedii ATCC 31812. The antibiotic and its cationic salts are active against a var...	11/30/1982

PatentStorm

Quotables

PatentStorm News

Assignee: Pfizer, Inc.